Long-acting injectable cabotegravir (CAB-LA) was recently shown in large clinical trials to be a safe and effective way to prevent HIV. However, it has been difficult or impossible for those at risk to access it in many locations around the world. This session will include a brief review about the use of CAB-LA for HIV pre-exposure prophylaxis as well as community concerns and ethical issues raised by the lack of access to it.